(Albany, USA) DelveInsight’s “Axillary Hyperhidrosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Axillary Hyperhidrosis, historical and forecasted epidemiology as well as the Axillary Hyperhidrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Axillary Hyperhidrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Axillary Hyperhidrosis Market Forecast
Some of the key facts of the Axillary Hyperhidrosis Market Report:
- The Axillary Hyperhidrosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Key Axillary Hyperhidrosis Companies: Botanix Pharmaceuticals, Sound Surgical Technologies, LLC., Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corporation, Persōn & Covey, Stratus Pharmaceuticals, Journey Medical Corporation, Allergan, AbbVie, Brickell Biotech, Dermavant Sciences, Dermata Therapeutics, Viatris, Candesant Biomedical, and others
- Key Axillary Hyperhidrosis Therapies: Sofpironium Bromide, VASE, Glycopyrronium Bromide, Meditoxin, glycopyrronium Topical Wipesl, and others
- In January 2024, InMode MD Ltd. offers the InMode Pro System with the Morpheus8 Applicator, a computerized device that produces radio frequency energy utilizing Fractional RF technology. The Morpheus8 Applicator, equipped with a 24-pin tip, is specifically designed for treating primary hyperhidrosis in the underarm area.
- There are currently too few and insufficient epidemiologic data on hyperhidrosis to establish accurate prevalence or impact estimates. According to DelveInsight analysts, there were 10,491,560 cases of axillary hyperhidrosis (AH) in the US as a whole
- Based on the HDSS scale, the degree of axillary hyperhidrosis was assessed. According to DelveInsight, 1,584,618 people had non-severe symptoms and roughly 1,716,670 people had severe symptoms in 2021
- In the US, there were 3,301,288 diagnosed cases of axillary hyperhidrosis (AH) overall in 2021.
- The prevalence of primary axillary hyperhidrosis in the population of Japan aged 5-64 years is 5.75% (males, 6.60%; females, 4.72%), according to a study by Murota et al. (2021).
- The Axillary Hyperhidrosis epidemiology based on gender analyzed that in the US, out of the total diagnosed cases of Axillary Hyperhidrosis in 2021, 93% accounted for primary hyperhidrosis and 7% accounted for secondary hyperhidrosis
- The Axillary Hyperhidrosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Axillary Hyperhidrosis pipeline products will significantly revolutionize the Axillary Hyperhidrosis market dynamics.
Axillary Hyperhidrosis Overview
Axillary hyperhidrosis is a condition characterized by excessive sweating in the underarm area, beyond what is necessary for thermoregulation. It is a form of focal hyperhidrosis and typically begins in adolescence or early adulthood. While not life-threatening, the condition can significantly impact quality of life by causing discomfort, social embarrassment, and challenges in daily activities.
The exact cause of axillary hyperhidrosis is not fully understood but is believed to involve overactivity of the eccrine sweat glands, triggered by overstimulation of the sympathetic nervous system. It often occurs without an underlying medical condition but may occasionally be secondary to other disorders like hyperthyroidism or certain medications.
Diagnosis is clinical, based on patient history and physical examination, with additional tests like the iodine-starch test used to assess sweating severity.
Treatment aims to reduce sweating and improve the patient’s quality of life. First-line options include topical antiperspirants containing aluminum chloride and prescription-strength formulations. Botulinum toxin (Botox) injections are highly effective for temporary relief. Other interventions include iontophoresis, microwave thermolysis, or surgical procedures like sympathectomy in severe cases. Emerging treatments, such as lasers and topical neurotoxins, offer promising alternatives.
Lifestyle modifications, including wearing breathable fabrics and avoiding triggers, complement medical interventions in managing axillary hyperhidrosis effectively.
Get a Free sample for the Axillary Hyperhidrosis Market Report: Axillary Hyperhidrosis Market Trends
Axillary Hyperhidrosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Axillary Hyperhidrosis Epidemiology Segmentation:
The Axillary Hyperhidrosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
- Total Prevalence of Axillary Hyperhidrosis
- Prevalent Cases of Axillary Hyperhidrosis by severity
- Gender-specific Prevalence of Axillary Hyperhidrosis
- Diagnosed Cases of Episodic and Chronic Axillary Hyperhidrosis
Download the report to understand which factors are driving Axillary Hyperhidrosis epidemiology trends @ Axillary Hyperhidrosis Epidemiology Forecast
Axillary Hyperhidrosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Axillary Hyperhidrosis market or expected to get launched during the study period. The analysis covers Axillary Hyperhidrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Axillary Hyperhidrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Axillary Hyperhidrosis Therapies and Key Companies
- Sofpironium bromide (BBI-4000): Botanix Pharma
- VASER: Sound Surgical Technologies, LLC.
- Glycopyrronium Bromide: Dr. August Wolff GmbH
- Meditoxin: Medy-Tox
- glycopyrronium Topical Wipes: Journey Medical Corporation
Discover more about therapies set to grab major Axillary Hyperhidrosis market share @ Axillary Hyperhidrosis Treatment Market
Scope of the Axillary Hyperhidrosis Market Report
- Study Period: 2019-2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Axillary Hyperhidrosis Companies: Botanix Pharmaceuticals, Sound Surgical Technologies, LLC., Dr. August Wolff GmbH, Medy-Tox, Journey Medical Corporation, Persōn & Covey, Stratus Pharmaceuticals, Journey Medical Corporation, Allergan, AbbVie, Brickell Biotech, Dermavant Sciences, Dermata Therapeutics, Viatris, Candesant Biomedical, and others
- Key Axillary Hyperhidrosis Therapies: Sofpironium Bromide, VASE, Glycopyrronium Bromide, Meditoxin, glycopyrronium Topical Wipes, and others
- Axillary Hyperhidrosis Therapeutic Assessment: Axillary Hyperhidrosis current marketed and Axillary Hyperhidrosis emerging therapies
- Axillary Hyperhidrosis Market Dynamics: Axillary Hyperhidrosis market drivers and Axillary Hyperhidrosis market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Axillary Hyperhidrosis Unmet Needs, KOL’s views, Analyst’s views, Axillary Hyperhidrosis Market Access and Reimbursement
To know more about Axillary Hyperhidrosis companies working in the treatment market, visit @ Axillary Hyperhidrosis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Axillary Hyperhidrosis Market Report Introduction
2. Executive Summary for Axillary Hyperhidrosis
3. SWOT analysis of Axillary Hyperhidrosis
4. Axillary Hyperhidrosis Patient Share (%) Overview at a Glance
5. Axillary Hyperhidrosis Market Overview at a Glance
6. Axillary Hyperhidrosis Disease Background and Overview
7. Axillary Hyperhidrosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Axillary Hyperhidrosis
9. Axillary Hyperhidrosis Current Treatment and Medical Practices
10. Axillary Hyperhidrosis Unmet Needs
11. Axillary Hyperhidrosis Emerging Therapies
12. Axillary Hyperhidrosis Market Outlook
13. Country-Wise Axillary Hyperhidrosis Market Analysis (2019-2032)
14. Axillary Hyperhidrosis Market Access and Reimbursement of Therapies
15. Axillary Hyperhidrosis Market Drivers
16. Axillary Hyperhidrosis Market Barriers
17. Axillary Hyperhidrosis Appendix
18. Axillary Hyperhidrosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services